Analysis from JBM Health economics provides rigorous validation of your product proposition.
Health Technology Assessment (HTA) agencies have been established throughout the world to address the tension between increasing demand and finite supply within healthcare systems. The pharmaceutical industry is now being challenged to demonstrate value of its products beyond the traditional clinical criteria. Accordingly, development and dissemination of robust health economic data is an essential component of successful product marketing.
Health Technology Assessment submissions
Health Technology Assessment submissions from JBM Health economics offer assurance that your product will be appropriately positioned in national guidelines.NICE is setting the standard for HTA and has significant potential to influence markets beyond the UK, particularly throughout Europe. The Institute has been subject to scrutiny by governments and healthcare providers worldwide and the potential for NICE guidance to impact on product sales is significant. Accordingly, successful outcome of a NICE product review is essential for UK marketing and is likely to positively influence reimbursement decisions elsewhere.
JBM offers a complete project management capability in relation to the development of NICE, SMC and AWMSG submissions. This service includes:
Facilitation and documentation of company task force meetings
Generation of epidemiological rationale for patient group selection
Critical appraisal of product evidence-base to support positioning
Fulfilment of HTA agency’s health economic modelling requirements
Production of fully referenced document for submission
Co-ordination of responses to consultation documents and draft guidance.
Our extensive in-house experience of disease modelling, clinical effectiveness appraisal and health economic analysis provide clients with the complete array of expertise required to develop the most robust clinical and economic case possible for product adoption aligned to your positioning needs.
In 2008-2009 we carried out five health technology appraisals, all of which were successfully submitted to bodies in the UK and Europe.
Health economics analysis
JBM Health economics can produce manuscripts and generate peer-reviewed publications for all types of health economic models. Our publications will generate essential supporting evidence for Health Technology Assessment submissions and also address local and/or regional medicines management group requirements.
Access to JBM's extensive expert network can create opportunities for the company team to collaborate with renowned authorities in the field. Furthermore, our considerable in-house experience of product marketing strategies ensures that your positioning needs are central to the publication plan and manuscript development.
Belsey JD. Cost effectiveness of oral triptan therapy: A trans-national comparison based on a meta-analysis of randomised controlled trials. Curr Med Res Opin 2004;20:659-669. View PubMed abstract.
